Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 928 results
Filters: Author is Bosch, Ronald J  [Clear All Filters]
Found 928 results.

Viremia

Gandhi RT, Coombs RW, Chan ES, et al. "No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2012;59(3):229-35.
Vardhanabhuti S, Taiwo B, Kuritzkes DR, Eron JJ, Bosch RJ. "Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia." Antivir. Ther. (Lond.). 2015;20(1):73-6.
Gandhi RT, Zheng L, Bosch RJ, et al. "The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial." PLoS Med.. 2010;7(8).
Zheng L, Bosch RJ, Chan ES, et al. "Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy." Antivir. Ther. (Lond.). 2013;18(1):39-43.
Gandhi RT, Bosch RJ, Aga E, et al. "Residual plasma viraemia and infectious HIV-1 recovery from resting memory CD4 cells in patients on antiretroviral therapy: results from ACTG A5173." Antivir. Ther. (Lond.). 2013;18(4):607-13.
Weinberg A, Tierney C, Kendall MA, et al. "Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviral therapy." J. Infect. Dis.. 2006;193(4):488-93.
Gandhi RT, McMahon DK, Bosch RJ, et al. "Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation." PLoS Pathog.. 2017;13(4):e1006285.
Kalayjian RC, Franceschini N, Gupta SK, et al. "Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease." AIDS. 2008;22(4):481-7.
Besson GJ, Lalama CM, Bosch RJ, et al. "HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy." Clin. Infect. Dis.. 2014;59(9):1312-21.
Volberding P, Demeter L, Bosch RJ, et al. "Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment." AIDS. 2009;23(15):1987-95.

Young Adult

Sandler NG, Zhang X, Bosch RJ, et al. "Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection." J. Infect. Dis.. 2014;210(10):1549-54.
Evans SR, Ellis RJ, Chen H, et al. "Peripheral neuropathy in HIV: prevalence and risk factors." AIDS. 2011;25(7):919-28.
Besson GJ, Lalama CM, Bosch RJ, et al. "HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy." Clin. Infect. Dis.. 2014;59(9):1312-21.
Tenorio AR, Zheng Y, Bosch RJ, et al. "Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment." J. Infect. Dis.. 2014;210(8):1248-59.
Taylor LE, Holubar M, Wu K, et al. "Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials." Clin. Infect. Dis.. 2011;52(6):812-8.
Tenorio AR, Chan ES, Bosch RJ, et al. "Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286." J. Infect. Dis.. 2015;211(5):780-90.
Smurzynski M, Wu K, Benson CA, Bosch RJ, Collier AC, Koletar SL. "Relationship between CD4+ T-cell counts/HIV-1 RNA plasma viral load and AIDS-defining events among persons followed in the ACTG longitudinal linked randomized trials study." J. Acquir. Immune Defic. Syndr.. 2010;55(1):117-27.
Lee AJ, Bosch RJ, Evans SR, et al. "Patterns of peripheral neuropathy in ART-naïve patients initiating modern ART regimen." J. Neurovirol.. 2015;21(2):210-8.

Pages